US$ 22.21
bpc-157 intervertebral disc regeneration study BPC 157 Nerve Regeneration: Top 2026 Breakthrough Clinical Development of Regenerative Medicine
Description
Novo Nordisk anticipates a decline in sales and profits from its GLP-1 drugs this year due to rising competition from Lilly

The Clinical Data: CagriSema Crushes Either Peptide Alone Let me give you the numbers that matter, straight from the Phase 3 REDEFINE trials published in the New England Journal of Medicine

Comparison with Standard Treatments Studies comparing BPC-157 to becaplermin (the active ingredient in Regranex, an FDA-approved treatment for diabetic foot ulcers) found BPC-157 produced superior results in several parameters

BPC157
